Registry record from ClinicalTrials.gov (NCT07617636). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: NOT_YET_RECRUITING. Study
Abstract Static biomarkers are increasingly failing to predict outcomes in hepatobiliary cancers, largely due to the profound heterogeneity of the tumor microenvironment. Over the
Multicohort observational analysis with consistent dose-response associations across three independent cohorts and plausible biological mechanism, but lacks randomized evidence of thymus-sparing intervention efficacy.